A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT ID: NCT07227311
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
200 participants
INTERVENTIONAL
2026-01-14
2030-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belantamab mafodotin + Pomalidomide + Dexamethasone (BPd)
Belantamab mafodotin
Belantamab mafodotin will be administered.
Dexamethasone
Dexamethasone will be administered.
Pomalidomide
Pomalidomide will be administered.
Belantamab mafodotin + Bortezomib + Dexamethasone (BVd)
Belantamab mafodotin
Belantamab mafodotin will be administered.
Dexamethasone
Dexamethasone will be administered.
Bortezomib
Bortezomib will be administered.
Belantamab mafodotin + Carfilzomib + dexamethasone (BKd)
Belantamab mafodotin
Belantamab mafodotin will be administered.
Dexamethasone
Dexamethasone will be administered.
Carfilzomib
Carfilzomib will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belantamab mafodotin
Belantamab mafodotin will be administered.
Dexamethasone
Dexamethasone will be administered.
Pomalidomide
Pomalidomide will be administered.
Bortezomib
Bortezomib will be administered.
Carfilzomib
Carfilzomib will be administered.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Applicable to All Arms - BPd, BVd, BKd:
* Male or female, 18 years or older (at the time consent is obtained).
* Have a confirmed diagnosis of Multiple Myeloma (MM) as defined by the International Myeloma Working Group (IMWG) criteria.
* Eastern Cooperative Oncology Group (ECOG) performance status of zero to 2.
* Have been previously treated with at least 1, but no more than 2, prior lines of MM therapy and must have documented disease progression during or after their most recent therapy.
* Must have at least 1 aspect of measurable disease, defined as one the following:
1. Urine M-protein excretion ≥200 mg/24 h, or
2. Serum M-protein concentration ≥0.5 g/dL (≥5.0 g/L), or
3. Free Light Chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum free light chain ratio (\<0.26 or \>1.65) only if patient has no measurable urine or serum M spike.
* Patients with a history of Autologous Stem Cell Transplant (ASCT) are eligible for study participation provided the following eligibility criteria are met:
1. ASCT was \>100 days prior to the first dose of study medication,
2. No active bacterial, viral, or fungal infection(s) present.
* All prior treatment-related toxicities (defined by National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v5.0) must be ≤Grade 1 at the time of enrollment, except for alopecia.
* Adequate organ system functions as defined by the laboratory assessments.
* Contraceptive requirements for men and women per local regulations; strict pregnancy prevention for women of childbearing potential (WOCBP), including negative pregnancy tests and use of highly effective contraception.
* Male participants must refrain from sperm donation and must use a condom plus an additional highly effective method of contraception if sexually active with a woman of childbearing potential.
• Prior treatment must include a lenalidomide-containing regimen, with lenalidomide administered for at least 2 consecutive cycles.
Exclusion Criteria
Applicable for all (BPd, BVd, BKd):
* Active plasma cell leukemia at Screening.
* Symptomatic amyloidosis, including active Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma proliferative disorder, and Skin changes (POEMS).
* Previous or concurrent invasive malignancy other than MM, except:
1. The disease must be considered medically stable for at least 2 years; or
2. The patient must not be receiving active therapy, other than hormonal therapy for this disease.
* Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
* Plasmapheresis within 7 days prior to the first dose of study intervention.
* Patients after prior allogeneic stem cell transplant
* Any major surgery within 4 weeks prior to start of treatment, except for bone stabilizing surgery.
* Evidence of active mucosal or internal bleeding.
* Intolerance or contraindications to anti-viral prophylaxis.
* Current corneal epithelial disease except for mild punctate keratopathy.
* Systemic anti-myeloma therapy (including chemotherapy and systemic steroids); prior treatment with an anti-MM monoclonal antibody drug within 30 days of receiving the first dose of study intervention.
* Presence of active renal condition (infection, requirement for dialysis, or any other condition that could affect participant's safety). Patients with isolated proteinuria resulting from MM are eligible, provided they fulfill certain criteria
* Received prior B-cell maturation antigen (BCMA)-targeted therapy.
* Contact lenses are prohibited while receiving belantamab mafodotin treatment. Use may be restarted after a qualified eye care specialist confirms there are no other contraindications. Bandage contact lenses are permitted during study treatment as directed by the treating eye care specialist.
* HIV infection unless well-controlled, no recent AIDS-defining infections, and adequate CD4+ count.
* Significant liver dysfunction (ALT \>2.5x ULN, bilirubin \>1.5x ULN, cirrhosis, unstable liver/biliary disease).
* Positive hepatitis B or C markers unless criteria for resolved infection are met.
* Evidence of cardiovascular risk including any of the following: untreated arrhythmias, recent MI/ACS/angioplasty/bypass, NYHA III/IV heart failure, uncontrolled hypertension, QTc prolongation.
* Received prior treatment with or intolerant to pomalidomide.
* Active or history of venous and arterial thromboembolism within the past 3 months.
* Intolerant to bortezomib or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m² twice weekly or within 60 days of completing that treatment).
* Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
* Intolerant to carfilzomib or refractory to carfilzomib (defined as progressive disease during treatment with a carfilzomib-containing regimen or within 60 days of completing that treatment).
* Known history of allergy to captisol (i.e., cyclodextrin derivatives) used to solubilize carfilzomib.
* Left ventricular ejection fraction \<40% as assessed by transthoracic echocardiogram.
* Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrolment.
* Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
* Known pulmonary hypertension.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
EU GSK Clinical Trials Call Center
Role: CONTACT
Phone: +44 (0) 20 89904466
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-523117-28-00
Identifier Type: CTIS
Identifier Source: secondary_id
224317
Identifier Type: -
Identifier Source: org_study_id